National Vulvodynia Association

Last year, 30 renowned vulvodynia researchers identified three promising new treatments for vulvodynia: maresin-1, resiniferatoxin and ketotifen fumerate. A pharmaceutical company has started a clinical trial of maresin-1 and a study of resiniferatoxin is under review at NIH.

In June, the NVA received a proposal to test the third promising treatment. Several animal studies have shown that ketotifen fumerate (KF) reduces inflammation of the vulva, so the next step is to test KF in women with vulvodynia. Please help NVA fund this clinical trial. You can donate online at www.nva.org/donate.